Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Revitope logo — Powered for Precision: Revolutionizing immunotherapy to safe...

Revitope

Powered for Precision: Revolutionizing immunotherapy to safely and effectively treat more cancers

Founded 2016 United States Cambridge, United States 6 employees Venture round Total: $8.50M Biotechnology, Health Care +1

General Information

Company Name Revitope
Founded Year 2016
Location United States Cambridge, United States
Employees 6
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Revitope. To contact Revitope, visit revitope.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Revitope compare?

A PDF of Revitope and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Revitope soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Revitope

Revitope, an early stage biotechnology company, is focused on revolutionizing immunotherapy to effectively treat a wide range of cancers. The company's Programmable Antibody Circuits (PACs) aim to redirect T cells to the surface of cancer cells, activating a potent immune response while expanding antigenic targeting space. Founded in 2014 in the United States, Revitope secured an $8.50M Venture Round investment on 08 February 2016. The company's innovative approach to immune-based therapies in cancer treatment positions it as a promising player in the Biotechnology and Health Care industries. Revitope's groundbreaking work in precision immunotherapy has the potential to significantly impact the future of cancer treatment.

Business keywords: immunotherapy, cancer treatment, T cell redirecting biologics, precision medicine, immune-based therapies, programmable antibody circuits, immunodominant viral peptide, cancer immunotherapy, biologic prodrugs, antibody technology, oncology, clinical studies, viral immune response, antigenic targeting

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $8.50M -
08 Feb 2016

Revitope Alternatives & Competitors

View All Alternatives
Revitope vs
Tolerx, Inc.
Tolerx, Inc. United States

Tolerx, Inc., a world leader in immunology, has a portfolio of innovative, first-in-class drug candi...

Venture round
9 employees
Biotechnology, Health Care
Revitope vs
ImmunoCellular Therapeutics Ltd
ImmunoCellular Therapeutics Ltd United States

Pioneering immune-based therapies to harness the body's defenses against cancer through advanced imm...

Grant
11 employees
Biotechnology, Health Care
Revitope vs
Provenance Biopharmaceuticals
Provenance Biopharmaceuticals United States

Building a future where the immune system stands strong against cancer and critical diseases with in...

Convertible Note
1 employees
Biotechnology, Health and Wellness
Also compare with: Revitope vs 3T Biosciences 3T Biosciences View all alternatives

FAQ About Revitope

Powered for Precision: Revolutionizing immunotherapy to safely and effectively treat more cancers
Revitope was founded in 2016.
Revitope is headquartered in Cambridge, United States.
Revitope operates in Biotechnology, Health Care and Health and Wellness. Its work centres on immunotherapy, cancer treatment, T cell redirecting biologics and precision medicine.
Revitope has approximately 6 employees.
Revitope has completed 1 funding round, raising a total of $8.50M. The latest funding stage is Venture round.
Top alternatives and competitors to Revitope include Tolerx, Inc., ImmunoCellular Therapeutics Ltd, Provenance Biopharmaceuticals, Elicio Therapeutics, ImCheck Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Revitope and Tolerx, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Revitope, https://bouncewatch.com/company/revitope, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes